BioMerieux snares stake in Knome

France's BioMerieux has acquired a 10 percent stake in Knome for $5 million and struck a deal to use the Cambridge, MA-based company's genome sequencing and analysis services. "The deal with Knome allows the group to strengthen its position in molecular biology and to create diagnostic tools for tomorrow," CM-CIC Securities analyst Arsene Guekam said in a research note. Story

Suggested Articles

A drug developed at Temple restores a mechanism in brain cells that prevents the toxic buildup of the proteins amyloid beta and tau in Alzheimer's.

Gilead is considering repositioning NUC inhibitor remdesivir as a treatment for the coronavirus now sweeping across parts of China.

Ipsen has paused a phase 3 trial of palovarotene after an interim analysis found it is unlikely to meet its primary efficacy endpoint.